Navigation Links
Moffitt Cancer Center Joins National Campaign To Implore Americans To Donate $1 To Accelerate Cancer Research
Date:5/9/2008

TAMPA, Fla., May 9 /PRNewswire/ -- The Cancer Research Alliance, an organization comprised of 12 of the nation's best cancer centers including Moffitt Cancer Center, is asking all 303 million Americans to exercise their power over cancer by stepping up and donating $1 to cancer research efforts this Mother's Day through Father's Day.

The campaign, dubbed the "Infinite Power of One(TM)" campaign has two key goals: to activate Americans everywhere to take matters into their own hands, join together and exercise their collective power over cancer, and second, to raise much needed dollars to accelerate innovative cancer research at the participating cancer centers.

The public can join the "Infinite Power of One(TM)" campaign by visiting the campaign's sponsor, http://www.celebrations.com from May 11 through June 15 to donate. After donating, each person will be asked to add his or her own photo to the "Infinite Power of One" Healing Mosaic to celebrate the infinite power that one person and one dollar can make on our health. Proceeds will benefit cancer research at all member cancer centers.

Located in Tampa, Florida, Moffitt Cancer Center (http://www.moffitt.org) is the only Florida-based cancer center with the NCI designation as a Comprehensive Cancer Center for its excellence in research and contributions to clinical trials, prevention and cancer control. Moffitt currently has 15 affiliates in Florida, one in Georgia and two in Puerto Rico. Additionally, Moffitt is a member of the National Comprehensive Cancer Network, a prestigious alliance of the country's leading cancer centers, and is listed in U.S. News & World Report as one of "America's Best Hospitals" for cancer, as well as for ear, nose and throat. Moffitt's sole mission is to contribute to the prevention and cure of cancer.

ABOUT THE CANCER RESEARCH ALLIANCE

Th
'/>"/>

SOURCE Moffitt Cancer Center
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Enterix Inc. Launches Its Point-of-Care Test for Colorectal Cancer Screening
2. Dana-Farber Cancer Institute Commences Phase 1 Trial With EntreMeds Selective Kinase Inhibitor
3. Fujifilm and the National Breast Cancer Foundation Provide Free Mammograms as Part of Images of Health Campaign
4. European Regulatory Agency Supports OPAXIO(TM) Brand Name for Cell Therapeutics Lung Cancer Drug
5. When to Wait and When to Treat? New Program Will Search for Biomarkers in Men With Prostate Cancer to Help Find an Answer
6. HER1 and HER3 VeraTag(TM) Assays are Now Available for Use in Development and Clinical Evaluation of Cancer Therapeutics
7. New Study Raises Questions About Prostate Cancer Therapies Targeting Insulin-Like Growth Factor Receptor
8. National Cancer Registrars Association and IMPAC Medical Systems Announce Best Paper Award Recipients
9. Sale of Colon Cancer Diagnostic Tool to Czech Republic
10. Aflac and the American Association for Cancer Research Unite to Issue Inaugural Aflac Career Development Award for Childhood Cancer Research
11. deCODE Discovers Fourth Major Set of Common Genetic Variants Linked to Risk of Estrogen Receptor-Positive Breast Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... July 29, 2015  AmnioChor Inc., an early stage ... very pleased to announce that the Musculoskeletal Transplant Foundation ... to invest in their seed round of development of ... storage capabilities. AmnioChor,s technology allows cryopreservation ... human stem cells living within those tissues. Amnion is ...
(Date:7/29/2015)... DIEGO , July 29, 2015  Pfenex Inc. ... 2015 financial results will be released on Thursday, August ... am Eastern Time, Pfenex management will host a conference ... business update.  A press release outlining the financial results ... the call. Please call 1-866-376-8058 (US) or ...
(Date:7/29/2015)... ... July 29, 2015 , ... The third Medical Innovation Impact Index (MI3) ... in particular, drug/device combinations. The current system received a score of 0 (range -10 ... Centered Innovation (iPCI) of Fairleigh Dickinson University’s ( FDU ) Rothman Institute of ...
(Date:7/29/2015)... QUEBEC CITY , July 29, 2015 /PRNewswire/ ... (the "Company") today announced it has selected an optimized ... important milestone in the development of a new ... The MAPK pathway represents a prime target for ... significant antitumor activities and survival benefits for B-Raf ...
Breaking Biology Technology:The Musculoskeletal Transplant Foundation Agrees to Invest in AmnioChor 2Pfenex To Report Second Quarter 2015 Results and Provide Business Update on Thursday, August 13, 2015 2Third Medical Innovation Impact Index Issued by Fairleigh Dickinson University’s Initiative for Patient-Centered Innovation (iPCI) 2Third Medical Innovation Impact Index Issued by Fairleigh Dickinson University’s Initiative for Patient-Centered Innovation (iPCI) 3Aeterna Zentaris Announces Optimized Erk Inhibitor Compounds For Further Development 2Aeterna Zentaris Announces Optimized Erk Inhibitor Compounds For Further Development 3
... ... announced results from the RE-COVER(TM) study investigating dabigatran etexilate (150 mg ... patients with acute VTE. Results of the trial were presented ... published online in the New England Journal of Medicine .(1) ...
... , NEW YORK, Dec. 4 ... of its IL-3R targeting agents, SL-401 and SL-501, in both ... (CML) have been selected for poster presentation at the upcoming 51st ... held in New Orleans from December 5-8, 2009. The poster will ...
... , DALLAS, Dec. 3 ... Board: ACCP), today provided an update on its European commercial ... a debilitating side effect of radiation treatment and chemotherapy. MuGard ... countries, including the UK, Germany, Italy, Norway, Greece and Sweden. ...
Cached Biology Technology:RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 2RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 3RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 4RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 5RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 6Stemline Therapeutics Announces Poster Presenting in vivo and Anti-Cancer Stem Cell Activity of SL-401 against Chronic Myeloid Leukemia (CML) at the 51st Annual Meeting of the American Society of Hematology (ASH) 2Access Pharmaceuticals Provides Update on MuGard Commercial Launch in Europe 2Access Pharmaceuticals Provides Update on MuGard Commercial Launch in Europe 3Access Pharmaceuticals Provides Update on MuGard Commercial Launch in Europe 4
(Date:7/21/2015)... GOTHENBURG, Sweden , July 21, 2015 ... sensor FPC1025. Already received as well as expected revenues in 2015 ... included in FPC,s communicated revenue guidance of approximately 2,200 MSEK for ... is a leading smartphone manufacturer in China ... selected FPC1 02 5 for Axon ...
(Date:7/20/2015)... 20, 2015  Acuity Market Intelligence,s latest research ... of Commerce and Privacy" forecasts that between 2014 ... will be downloaded to smart mobile devices by ... market is projected to generate more than $67.9 ... seven-year forecast period.    "Biometrics is ...
(Date:7/9/2015)... 9, 2015  Synaptics Inc. (NASDAQ: SYNA ), a ... it will report financial results for the fourth quarter ... after the close of market. The company will host ... 2:00 p.m. PT (5:00 p.m. ET), during which management ... on the live call, analysts and investors should dial ...
Breaking Biology News(10 mins):FPC's Touch Fingerprint Sensor FPC1025 in ZTE's Smartphone Axon 2Biometrics on Smart Mobile Devices to Redefine Digital Identity with 12.9 Billion Biometric App Downloads between 2014 and 2020 2Synaptics to Report Fourth Quarter, Fiscal Year 2015 Results on July 30 2
... out of the George Washington University (GW), published in ... Sciences ( PNAS ), reveals another piece of ... behavioral diseases such as autism. Anthony-Samuel LaMantia, Ph.D., professor ... Medicine and Health Sciences (SMHS) and director of the ...
... press credentials for the American Chemical Society,s 245th National Meeting ... New Year will be held April 7-11, 2013, in New ... and others expected to gather in the Crescent City for ... from astronomy to zoology ― the meeting will offer ...
... keep their cellular calcium concentration at a very low ... many critical cellular functions (an elevated calcium concentration over ... mechanisms ensure that calcium concentration quickly returns to its ... of cellular calcium regulation underlie almost all neurodegenerative diseases. ...
Cached Biology News:GW professor discovers new information in the understanding of autism and genetics 2Press registration opens for 2013 meeting of world's largest scientific society 2
...
...
RatTRAPTM Assay is a solid-phase immunofixed enzyme activity assay for the determination of osteoclast-derived TRACP 5b activity in rat serum....
Applications include ELISA, immunochemistry, and Western blotting. Working Concentrations: ELISA: 0.005-0.05 U/ml, immunohisto/cytochemistry: 0.25-0.5 U/ml, Western blot: 0.1-0.25 U/ml....
Biology Products: